



Welcome

Welcome to the EndoNET New Year Newsletter. We hope you had an enjoyable festive break.

Whilst we continue to recruit, we were expecting faster recruitment, and for the continued success of the trial we would be grateful for all of your help supporting us in this. In the last quarter, the proportion of patients declining the trial was slightly up but this coincided with the overall number of patients being approached falling. If we had approached as many patients in the second half of the year as we did in the first half of 2025, we would likely be on target. Please continue to screen and then approach as many eligible patients as possible. We only need marginal gains at **every** site to make a significant difference to the performance of the trial.

From a more positive perspective as we head into the New Year, we are ready to **greenlight Trans-EndoNET** and will open at multiple sites shortly. We have made significant progress with the Nested Qualitative Study with over 10 interviews now completed. We have opened EndoNET at Doncaster and Worcester Royal recruited their first patient. We have also made progress towards opening internationally.

Our New Year's resolution is to open more sites domestically, set up internationally, and ensure that we are providing as much as we can to support you to recruit.

EndoNET Recruitment Championship

The **quarterly winner** for recruiting x3 patients is Oxford. Llandough, Rotherham and Wythenshawe just missed out with x2 patients each. We need to continue to push on in 2026 so next quarter we will reward sites that recruit x3 or more patients.

Site	Recruited Oct-Dec 2025	Total Randomised
Churchill (Oxford)	3	31
Basildon	1	27
Southampton	1	24
Castle Hill	1	16
Rotherham	2	15
Glenfield	1	12
Whiston	0	12
Nottingham City	0	11
Southend	0	11
Torbay	0	11
Yeovil	0	11
Royal Devon & Exeter	0	10
Royal Hampshire	0	8
Cumberland Infirmary	0	6
RAEI	1	6
Llandough	2	5
St Albans	0	5
QE Birmingham	0	4
Southmead	0	3
Wythenshawe	2	3
Aberdeen RI	0	2
Barnsley	0	2
Belfast City	0	2
Hairmyres	0	2
Royal Berks	1	2
Altnagelvin	0	1
Luton and Dunstable	0	1
Worcestershire Royal	1	1
Grand Total	16	244

* The 10 sites yet to recruit are not included in the recruitment table.

Screening Logs

Please make sure all of your screening logs are up to date and completed in



REDCap so that we can monitor activity and use the data to inform future refreshers and training.





Recruitment Tips

We know that you're all putting in an exceptional amount of work to support a number of different clinical studies. To ensure the time that you do spend on EndoNET is optimised, this page is full of our top recruitment tips, some of the more generic information may also help you to recruit to other trials.

Study or Trial? – Most patients accept clinical trial as a common term but QRI findings suggest using the term 'trial' can introduce notions of trial and error. QRI research has found that using the term 'study' is more acceptable to patients and fits with EndoNET as both arms are NHS approved pathways.

The patient should be given the **Patient Information Sheet** and the option to watch the **study video** at the earliest opportunity. An informed patient is likely to be more open-minded and this will save time discussing the study in clinic.

Teamwork – The whole team is important for recruitment to any trial. Consider everyone that needs to be pulled together for the success of the study. We're happy to present to your MDT to help facilitate this

Watch the EndoNET video here:
<https://youtu.be/7TY0Et9A8w4>

Treatment Starts Immediately

According to the screening logs and your feedback, the main reason for patients declining EndoNET is patients saying that they don't want to 'delay' treatment or surgery. It's good to stress that with EndoNET, treatment starts immediately on randomisation with endocrine therapy. All treatments for cancer are now a combination of different modalities of which surgery and endocrine therapy are both part. The study aims to determine whether the timing of surgery can be optimised in conjunction with endocrine therapy. See the QRI narrative below for suggestions on how to explain the combining of treatments in the study.



How to Communicate EndoNET to Patients – the QRI Narrative

